US biotechnology company modernclaimed to own the patent for the mRNA technology. German biotechnology company BioNTech and US-based pharmaceutical company Pfizer patent alleging a violation case opening Moderna, Pfizer-BioNTechmRNA technology patented by Moderna between 2010 and 2016, Covid-19 claimed that they copied it during the development of the vaccine.
“PFIZER AND BIONTECH COPY THIS TECHNOLOGY WITHOUT MODERNA’S PERMISSION”
In a statement made by Moderna, “Moderna believes that Comirnaty, the Covid-19 vaccine developed by Pfizer and BioNTech, infringes on Moderna’s patents covering the mRNA technology it found between 2010 and 2016. This breakthrough technology mRNA is Moderna’s own Covid-19 vaccine. The -19 vaccine was critical to the development of Spikevax. Pfizer and BioNTech copied this technology without Moderna’s permission to make the Comirnaty vaccine. First, Pfizer and BioNTech included 4 different options from Moderna’s innovative way. vaccine included the candidate in clinical testing. But they eventually decided to move forward with a vaccine with the same mRNA chemical modification as Moderna’s Spikevax vaccine. “Also, although they still have many different options, Pfizer and BioNTech have also replicated Moderna’s full-length spike protein coding approach for Covid-19, which causes Middle East Respiratory Syndrome (MERS).
class=”medianet-inline-adv”>
“PFIZER AND BIONTECH ARE USING MODERNA’S INVENTIONS WITHOUT PERMISSION”
Moderna in the U.S. District Court of Massachusetts and GermanyHe said that a compensation case was filed at the Düsseldorf District Court in , without specifying the amount. Stephane Bancel, CEO of Moderna, said in a statement: “We have invested billions of dollars in developing these cases, dollar Moderna Legal Director Shannon Thyme Klinger said, “Pfizer and BioNTech have illegally copied Moderna’s inventions and continue to use them without permission. We think they do. “Moderna expects Pfizer and BioNTech to compensate for continued use of Moderna’s proprietary technologies, except in poor countries.”
class=”medianet-inline-adv”>
HE SAID HE WOULD NOT CLAIM COMPENSATION
Consistent with its commitment to fair global access early in the outbreak, Moderna said it would not apply Covid-19 patents to help other companies develop their own Covid-19 vaccines, especially for low- and middle-income countries. But in March 2022, Moderna said it expected companies like Pfizer and BioNTech to respect its intellectual property rights. On the other hand, the company said that it will not seek compensation for any activity before March 8, 2022, adding, “Aware of the need to ensure continued access to these life-saving vaccines, Moderna is not considering removing the Comirnaty vaccine of Biontech and Pfizer from the market and is requesting an injunction to prevent its future sale. “Moderna also does not seek compensation for Pfizer’s sales to developing countries. In line with Moderna’s patent commitment, the company also does not seek compensation for activities that occurred before March 8, 2022.”
class=”medianet-inline-adv”>
OTHER COMPANIES HAVE ALSO FILED A CASE
The U.S. Food and Drug Administration (FDA) gave emergency use permission for the Covid-19 vaccine first to Pfizer-BioNTech in December 2020, and then to Moderna a week later. On the other hand, CureVac company, which said that the partnership of Pfizer and BioNTech violated patents, filed a lawsuit against BioNTech in Germany in July. BioNTech made a statement on the subject stating that their work was original.
.